After Colorado’s prescription drug affordability board (PDAB) ruled Trikafta “not unaffordable” largely in part from patient assistance programs offered by the manufacturer, a bill introduced in the state’s legislature would not allow for Trikafta -- or any other orphan drug -- from being considered by the new board. Colorado’s PDAB said in its report that it would consider reviewing Trikafta in the future if patients’ access to the drug subsided. Pharmaceutical Research and Manufacturers of America has donated over $800,000...